Liver function is a key factor that can help predict the clinical outcome in patients with cirrhosis. Traditionally, liver function was measured using either indocyanine green (ICG) or other radionucleotides. Recently, gadoxetic acid has been reported to show liver function in several studies. There have been several approaches to measure liver function using gadoxetic acid, and hepatocyte fraction is one of the promising methods. Since gadoxetic acid enhanced liver MRI is clinically used world widely, it would be valuable if we can measure liver function using hepatocyte fraction.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
54
Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction. Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution.
ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
Seoul National University Hospital
Seoul, South Korea
Liver function assessed by hepatocyte fraction
hepatocyte fraction obtained by T1 map sequence
Time frame: 1 month after MRI
Liver function assessed by ICG R15 test
Time frame: 3 days after MRI
Hepatocyte uptake rate
calculated hepatic uptake rate from T1 map sequence at MRI
Time frame: 1 month after MRI
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.